Quantum dots found to reduce fibrils in Parkinson's mouse models

Quantum dots found to reduce fibrils in Parkinson's mouse models
TEM images of preformed α-syn fibrils at various time points (6 and 12 h, 1, 3 and 7 days) in the absence (top) and presence (bottom) of GQDs. Credit: Nature Nanotechnology (2018). DOI: 10.1038/s41565-018-0179-y

A large team of researchers with members from several institutions in the U.S., Korea and Japan has found that injecting quantum dots into the bloodstreams of mice led to a reduction in fibrils associated with Parkinson's disease. In their paper published in the journal Nature Nanotechnology, the group describes their studies of the impact of quantum dots made of graphene on synuclein and what they found.

Quantum dots are particles that exist at the nanoscale and are made of . Because they exhibit , scientists have been conducting experiments to learn more about changes they cause to organisms when embedded in their cells. In this new effort, the researchers became interested in the idea of embedding in synuclein cells.

Synucleins make up a group or family of proteins and are typically found in neural tissue. One type, an alpha-synuclein, has been found to be associated with the formation of fibrils as part of the development of Parkinson's disease. To see how such a protein might react when exposed to quantum dots, the researchers combined the two in a and watched what happened. They found that the quantum dots became bound to the protein, and in so doing, prevented it from clumping into fibrils. They also found that doing so after had already formed caused them to come apart. Impressed with their findings, the team pushed their research further.

Noting that quantum dots are small enough to pass through the blood/brain barrier, they injected quantum dots into mice with induced Parkinson's disease and monitored them for several months. They report that after six months, the mice showed improvements in symptoms.

The researchers suggest that quantum dots might have a similar impact on multiple ailments where fibrilization occurs, noting that another team had found that injecting them into Alzheimer's mouse models produced similar results.

It is still not known if injecting similar or different types of quantum dots into human patients might have the same effect, they note. Nor is it known if doing so would have any undesirable side effects. Still, the are optimistic about the idea of using quantum dots for treatment of such diseases and because of that, have initiated plans for testing with other animals—and down the road they are looking at the possibility of conducting clinical trials in humans.


Explore further

Gold changes photoluminescence of silicon quantum dots

More information: Donghoon Kim et al. Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease, Nature Nanotechnology (2018). DOI: 10.1038/s41565-018-0179-y

Abstract
Though emerging evidence indicates that the pathogenesis of Parkinson's disease is strongly correlated to the accumulation1,2 and transmission3,4 of α-synuclein (α-syn) aggregates in the midbrain, no anti-aggregation agents have been successful at treating the disease in the clinic. Here, we show that graphene quantum dots (GQDs) inhibit fibrillization of α-syn and interact directly with mature fibrils, triggering their disaggregation. Moreover, GQDs can rescue neuronal death and synaptic loss, reduce Lewy body and Lewy neurite formation, ameliorate mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn pathology provoked by α-syn preformed fibrils5,6. We observe, in vivo, that GQDs penetrate the blood–brain barrier and protect against dopamine neuron loss induced by α-syn preformed fibrils, Lewy body/Lewy neurite pathology and behavioural deficits.

Journal information: Nature Nanotechnology

© 2018 Medical Xpress

Citation: Quantum dots found to reduce fibrils in Parkinson's mouse models (2018, July 10) retrieved 21 May 2019 from https://phys.org/news/2018-07-quantum-dots-fibrils-parkinson-mouse.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
154 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more